Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2
Description
Novel targeting agents for hematologic diseases often exert on- or off-target immunomodulatory effects, possibly impacting on response to anti-SARS-CoV-2 vaccinations and other vaccines. Agents that primarily affect B cells, particularly anti-CD20